Steris Stock Forecast, Price & News

Steris' stock was trading at $145.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STE shares have increased by 17.2% and is now trading at $170.21.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Steris in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Steris.

Steris is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Steris.

Steris PLC (NYSE:STE) released its earnings results on Monday, August, 3rd. The medical equipment provider reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.98 by $0.33. The medical equipment provider had revenue of $668.90 million for the quarter, compared to the consensus estimate of $643.38 million. Steris had a return on equity of 16.24% and a net margin of 13.69%. The company's revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period last year, the firm posted $1.23 earnings per share.
View Steris' earnings history.

Steris announced a quarterly dividend on Monday, August 3rd. Investors of record on Thursday, August 27th will be given a dividend of $0.40 per share on Thursday, September 24th. This represents a $1.60 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Wednesday, August 26th. This is a positive change from Steris's previous quarterly dividend of $0.37.
View Steris' dividend history.

4 equities research analysts have issued 1 year price targets for Steris' stock. Their forecasts range from $170.00 to $175.00. On average, they expect Steris' stock price to reach $172.50 in the next year. This suggests a possible upside of 1.3% from the stock's current price.
View analysts' price targets for Steris.

Steris saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,140,000 shares, an increase of 24.0% from the August 15th total of 919,500 shares. Based on an average daily volume of 459,000 shares, the short-interest ratio is currently 2.5 days.
View Steris' Short Interest.

Some companies that are related to Steris include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), Teleflex (TFX) and Insulet (PODD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Steris investors own include Johnson & Johnson (JNJ), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Gilead Sciences (GILD), Home Depot (HD), Pfizer (PFE), AT&T (T), Mastercard (MA) and Medtronic (MDT).

Steris trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

Steris' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.18%), WCM Investment Management LLC (7.41%), William Blair Investment Management LLC (1.44%), ArrowMark Colorado Holdings LLC (1.36%), Bessemer Group Inc. (1.09%) and Bank of America Corp DE (1.04%). Company insiders that own Steris stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, Jacqueline B Kosecoff, John Adam Zangerle, Karen L Burton, Kathleen Bardwell, Loyal W Wilson, Michael B Wood, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden, Richard Martin Steeves, Walter M Rosebrough Jr and Walter M Rosebrough, Jr.
View institutional ownership trends for Steris.

STE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., Vanguard Group Inc., Fisher Asset Management LLC, Assenagon Asset Management S.A., Nuveen Asset Management LLC, Two Sigma Advisers LP, and Robeco Institutional Asset Management B.V.. Company insiders that have sold Steris company stock in the last year include Cary L Majors, Daniel A Carestio, John Adam Zangerle, Mohsen Sohi, Richard C Breeden, and Richard Martin Steeves.
View insider buying and selling activity for Steris.

STE stock was bought by a variety of institutional investors in the last quarter, including WCM Investment Management LLC, Great West Life Assurance Co. Can, FIL Ltd, TimesSquare Capital Management LLC, Retirement Systems of Alabama, Bank of America Corp DE, Principal Financial Group Inc., and Principal Financial Group Inc..
View insider buying and selling activity for Steris.

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STE stock can currently be purchased for approximately $170.21.

Steris has a market capitalization of $14.48 billion and generates $3.03 billion in revenue each year. The medical equipment provider earns $407.61 million in net income (profit) each year or $5.64 on an earnings per share basis. Steris employs 13,000 workers across the globe.

The official website for Steris is www.steris.com.

Steris' mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at 353-1232-2000 or via email at [email protected]